Uncategorized
Maze Loses Nearly a Third of Market Cap on Mixed Midstage Kidney Drug Data
Besting Vertex Pharmaceuticals’ kidney disease asset wasn’t enough to impress Wall Street, which appears to be “getting hung up” with the broad population data in Maze Therapeutics’ trial, according to Mizuho.